An observational study in Substance Use Disorders and Substance Use, sponsored by University of Huelva. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-24.
Sponsored by University of Huelva · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Substance-Related Disorders with a site in Spain — 6 open to participants now, 7 under way, none of them phase 3. Substance-Related Disorders · Spain.
Among the 26 studies in Substance-Related Disorders with a site in Spain, this one is one of 3 that started in 2023, is one of 6 observational ones, and was the 21st registered.
2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.
Browse Substance-Related Disorders studies →6 of the 26 studies in Substance-Related Disorders with a site in Spain are open now. Recruiting first, the newest first:
Clínica Nuestra Señora de la Paz · Sites in Spain
Ages 18–90
Hospital Virgen del Puerto · Sites in Spain
Ages 18+
NORCE Norwegian Research Centre AS · Sites in Spain, Austria, Israel and 5 more countries
Ages 18+
University of Santiago de Compostela · Sites in Spain
Ages 40+ · Healthy volunteers
University of Valencia · Sites in Spain
Ages 18+ · Men only
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2023.
This study's planned enrollment of 130 is below the median of 250 across 299 observational studies indexed under Substance-Related Disorders.
Median enrollment 131 across the 20 interventional studies, 403 across the 6 observational. Of the 12 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 26 have an industry lead sponsor. The 10 most frequent:
University of Huelva is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
University of Huelva has 1 study filed under Substance-Related Disorders — fewer than ten, so there is no comparison to draw.
2 of the studies in Substance-Related Disorders with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07052175Clínica Nuestra Señora de la PazPrevention of Relapse in Behavioral Disorders | 2026-12 |
| NCT07443033Hospital Virgen del PuertoPsychosocial Factors in Dual Diagnosis in a General Hospital | 2027-04-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 26 studies in Substance-Related Disorders with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This longitudinal repeated measures study will evaluate participants at the beginning of treatment through an assessment of psychological measures and craving. They will be trained to use a mobile platform, which will be available for 12 days. The assessment will be conducted via Ecological Momentary Assessment (EMA), with scheduled daily access and during situations of consumption risk. Each access will include questions on substance use, depression, anxiety, triggering situations, attitude towards drugs, and a cognitive bias test. The platform will alternate between two tests (Drug Stroop Task and WAT-DUD). Participants will follow a treatment program supervised by professionals.
The study aims to recruit 130 participants (65 for alcohol, 65 for cocaine) from the Provincial Service for Drug Dependence and Addictions in Huelva (SPDA). Participants, selected via stratified random sampling, must reside in Huelva, sign informed consent, have a compatible mobile device, and be over 18. Anonymity will be ensured through alphanumeric codes.
Upon treatment admission, selected patients will be informed of their participation in the study. Interviews, conducted by psychologists, will outline the study objectives and duration. Patients agreeing to participate will sign informed consent and receive an identification code. Baseline assessment data will be integrated into a database for subsequent statistical analysis. The assessment encompasses the collection of four blocks of information:
Block 1. Patients medical history initiated during treatment admission. Block 2. Neuropsychological battery developed by the research team for the baseline evaluation.
Block 3. Neuropsychological battery developed by the research team for the web platform measured through Ecological Momentary Assessment (EMA).
Block 4. Follow-up information at three and six months provided by SPDA professionals through the patients medical history.
To ensure compliance with participant follow-up, a mixed monitoring protocol has been developed, which includes phone calls and WhatsApp messages. This protocol is designed according to social exchange theory so that participants perceive the benefits of their participation as outweighing the costs.
The statistical analysis involves identifying outliers and trimming distributions. Data will be averaged per test per person, considering different conditions. Repeated measures ANOVA will analyze factors such as gender and substance type to address study objectives, examining interactions and conducting planned contrasts for specific comparisons.
The assessment encompasses the collection of four blocks of information:
Block 1. Patients medical history initiated during treatment admission. The following information will be gathered:
a) Consumption pattern during the 30 days prior to treatment initiation b) Sociodemographic information collected by center professionals.
Block 2. Neuropsychological battery developed by the research team for the baseline evaluation. The estimated time is 90 minutes, including training in the use of the platform. The following tests will be used:
Questionnaire developed by the research team including sociodemographic information and gender-related variables.
State/Trait Depression Inventory (IDER). Craving: Multidimensional Alcohol Craving Scale (EMCA). Cocaine Craving Questionnaire-Now (CCQ-N-10).
Monetary Choice Questionnaire (MCQ). Iowa Gambling Task (IGT). Balloon Analogue Risk Task (BART). Impulsive Behavior Scale (UPPS-P). Anxiety Sensitivity Index (ASI-3). Positive and Negative Affect Schedule (PANAS). Acceptance and Action Questionnaire-II (AAQ-II). Padua Inventory.
Block 3. Neuropsychological battery developed by the research team for the web platform measured through Ecological Momentary Assessment (EMA). The following tests will be utilized:
Cognitive bias assessment: Each access to the platform (DA or TA) will include one of these two tests in an alternate sequence for each participant.
Drug Stroop Task for mobile devices. Word Association Task for Drug Use Disorder (WAT-DUD)
Craving assessment: The test are administered on days 1, 4, 8, and 12, and on each TA.
Multidimensional Alcohol Craving Scale (EMCA). Cocaine Craving Questionnaire-Now (CCQ-N-10).
Subjective anxiety. This question is included at the end of the IDER items. Attitude towards the drug. These questions are integrated into the craving questionnaires (EMCA/CCQ-N-10).
Triggering situation: These questions are integrated into the craving questionnaires (EMCA/CCQ-N-10).
Consumption during follow-up: These questions are presented independently from the rest of the tests before completing each access to the platform.
Before concluding the last two blocks related to the developed neuropsychological battery, it is worth noting that a series of control questions have been included to ensure greater reliability in participants responses. These questions have been included in both the baseline assessment tests and those presented during the EMA follow-up.
Block 4. Follow-up information at three and six months provided by SPDA professionals through the patients medical history: current situation, adherence level, level of involvement according to professional assessment, current substance use and relapses.
To ensure compliance with participant follow-up, a mixed monitoring protocol has been developed, which includes phone calls and WhatsApp messages. This protocol is designed according to social exchange theory so that participants perceive the benefits of their participation as outweighing the costs. Once SPDA professionals provide participant contact information and obtain consent for contact, an initial contact will be made via WhatsApp to schedule a baseline assessment appointment. If there is no response, a phone call will be made. When participants complete the baseline assessment, they will be taught how to use the platform, and the time window for data collection will be established. Participants will receive a welcome and motivation or pre-notification message, which includes elements of personalization and trust, tangible and intangible benefits of study participation, and cost minimization. At the designated time, a notification message will be sent, reminding participants of access hours and providing a direct link to the platform to minimize response costs. If participants do not access the platform daily during the established time window, a reminder message will be sent, even if they are no longer within the mentioned temporal window. This reminder will emphasize the benefits of study participation and provide a link to minimize response costs. If, despite reminders, participants do not access the platform for two consecutive days, a phone call will be made to encourage active participation. After completing the follow-up, a final thank-you message will be sent to participants, informing them of the amount of gift cards they will receive. They will also be reminded that their participation will help others and improve future interventions.
Statistical analysis. First, an analysis will be conducted to identify outliers in the individual responses to the items of each execution of each PSC. Distributions with outliers will be handled by trimming to the 90th percentile, transforming the considered outliers to the equivalent of the 5th and 95th percentiles of the distribution. Subsequently, the average value will be calculated for each test per person based on other variables (distinguishing between daily tests and impulse tests, as well as tests conducted on days of substance consumption versus days of non-consumption). This way, each participant will have an estimated value in the performance of each test under different access conditions (daily and impulse) and under the circumstances of substance consumption or non-consumption. To address the study objectives, data will be analyzed using a repeated measures ANOVA model. This model will have three factors forming different groups of participants (gender, primary substance, and type of admission) and two factors of repeated measures (type of measurement - impulse or daily - and substance consumption on the day of measurement). The full factorial model will be initially analyzed, which examines all main effects and all interactions. If any of the interactions are statistically significant, the results will be analyzed through decomposition into simple effects, as well as the estimation of the magnitude of the interaction. Comparisons for specific objectives will be conducted through planned contrasts.
Individuals receiving treatment for Substance Use Disorder (SUD) at the Provincial Service for Drug Dependence and Addictions (SPDA) in the province of Huelva, Spain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Differences between daily access scores and temptation access scores
We may find statistically significant differences between the scores obtained during episodes of temptation to consume or purchase substances and those obtained from daily measures, with higher scores during temptation episodes. These differences will be observed in both groups, among both men and women.
Time frame: Through study completion, an average of 2 years
Relationship between number of episodes of temptations and scores in the tests
It may be that during the monitoring, those participants who experience a higher number of episodes of temptation will have elevated levels in the scheduled measures. Those participants who have higher scores during episodes of temptation will have a greater number of episodes of consumption. These relationships will be observed in both groups, among both men and women.
Time frame: Through study completion, an average of 2 years
Differences based on the type of substance
There may be statistically significant differences in the test scores based on the type of substance.
Time frame: Through study completion, an average of 2 years
Relationship between the studied variables and variables associated with gender.
We may find differences in test scores based on gender-related variables.
Time frame: Through study completion, an average of 2 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for Aug 2025, 25 months after the start.
Of 123 non-industry observational studies under Substance-Related Disorders, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 60. This study's planned 25 months is below that.
Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 18 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Huelva